Exploring position of colchicine in management of COVID 19 – A systematic review
Abstract
Introduction: One of the goals of managing COVID 19 patients is controlling inflammatory responses, which are majorly responsible for morbidity and mortality associated with SARS CoV 2 infection. A novel approach to address inflammation could be Colchicine. It invariably decreases pulmonary complexities, showing antimitotic action, causing metaphase arrest by inhibiting microtubule and spindle formation, and is effective in reducing granulocyte migration, ultimately reducing inflammation.
Method: For this systemic review, literature was searched using PubMed, Embase, Cochrane Central, medRxiv, and researchsquare.com. The keywords used were – COVID 19, colchicine, SARS-CoV-2, and clinical outcome. Studies published between January 2020 and October 2021 were evaluated and screened to identify those that had reported the effect of colchicine in SARS CoV 2 infected patients and to assess clinical outcomes including mortality, intensive care unit (ICU) admissions, or mechanical ventilation.
Results and Discussion: In this systematic review among 8 quantitative clinical researchers, it was observed that colchicine administration was related to improved clinical outcomes in COVID 19 patients, without statistical significance.
Conclusion: The mortality risk of COVID-19 patients can be reduced by colchicine. Need more prospective clinical researches which could help to evaluate the efficacy of colchicine to treat COVID-19 patients in different stages of the disease, including post-hospitalization and long-term care follow-up.
Downloads
References
Akhmerov, A. & Marbán, E. (2020). COVID-19 and the heart. Circ Res, 126,1443–55
Brunetti, L., Diawara, O., Tsai, A., Firestein, B. L., Nahass, R. G., Poiani, G., & Schlesinger, N. (2020). Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of clinical medicine, 9(9), 2961.
Chiu L, Lo C-H, Shen M, Chiu N, Aggarwal R, Lee J, et al. (2021) Colchicine use in patients with COVID-19: A systematic review and meta-analysis. PLoS ONE 16(12): e0261358.
Deftereos, S. G., Giannopoulos, G., Vrachatis, D. A., Siasos, G. D., Giotaki, S. G., Gargalianos, P., Metallidis, S., Sianos, G., Baltagiannis, S., Panagopoulos, P., Dolianitis, K., Randou, E., Syrigos, K., Kotanidou, A., Koulouris, N. G., Milionis, H., Sipsas, N., Gogos, C., Tsoukalas, G., Olympios, C. D., … GRECCO-19 investigators (2020). Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA network open, 3(6), e2013136.
Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 | medRxiv [Internet]. [cited 2021 Jan 30]. Available from: https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1
Elshafei, M. N., El-Bardissy, A., Khalil, A., Danjuma, M., Mubasher, M., Abubeker, I. Y., & Mohamed, M. (2021). Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis. European journal of clinical investigation, 51(9), e13645.
Katsanos, A.H., Palaiodimou, L., Price, C., Themistocleous, M., Lemmens, R., Michopoulos, I., Georgakis, M.K., Weimar, C., Kelly, P.& Tsivgoulis, G. (2021). An Updated Meta-Analysis of RCTs of Colchicine for Stroke Prevention in Patients with Coronary Artery Disease. J. Clin. Med., 10, 3110.
Lopes, M. I., Bonjorno, L. P., Giannini, M. C., Amaral, N. B., Menezes, P. I., Dib, S. M., Gigante, S. L., Benatti, M. N., Rezek, U. C., Emrich-Filho, L. L., Sousa, B., Almeida, S., Luppino Assad, R., Veras, F. P., Schneider, A., Rodrigues, T. S., Leiria, L., Cunha, L. D., Alves-Filho, J. C., Cunha, T. M., … Oliveira, R. (2021). Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD open, 7(1), e001455.
Mareev, V.Y., Orlova, Y.A., Plisyk, A.G., Pavlikova, E.P., Akopyan, Z.A., Matskeplishvili, S.T., Malakhov, P.S., Krasnova, T.N., Seredenina, E.M., Potapenko, A.V., Agapov, M.A., Asratyan, D.A., Dyachuk, L.I., Samokhodskaya, L.M., Mershina, Е.А., Sinitsyn, V.E., Pakhomov, P.V., Zhdanova, E.A., Mareev, Y.V., Begrambekova, Y.L. & Kamalov, А.А. (2021). Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. Kardiologiia, 61(2), 15-27
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., & HLH Across Speciality Collaboration, UK (2020). COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England), 395(10229), 1033–1034.
Nieto-Torres, J. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Torres, J., Aguilella, V. M., & Enjuanes, L. (2015). Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome. Virology, 485, 330–339.
Nonaka, D., Takase, H., Machii, M., & Ohno, K. (2020). Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: A case report. Medicine, 99(16), e19814.
RECOVERY Collaborative Group (2021). Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. Respiratory medicine, 9(12), 1419–1426.
Rodriguez-Nava, G., Trelles-Garcia, D.P., Yanez-Bello, M.A., Chung, C.W., Trelles-Garcia, V.P. & Friedman HJ. (2020) Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care, 24(1),1–2.
Samajdar, S.S., Sam, P.A., Moitra, S., Ray, Y., Pal, J., Joshi, S.R. & Tripathi, S.K. (2020). Risk Benefit Analysis in Reference to use of LMWH in COVID-19. J Assoc Physicians India , 68(9), 52-61.
Scarsi, M., Piantoni, S., Colombo, E., Airó, P., Richini, D., Miclini, M., Bertasi, V., Bianchi, M., Bottone, D., Civelli, P., Cotelli, M. S., Damiolini, E., Galbassini, G., Gatta, D., Ghirardelli, M. L., Magri, R., Malamani, P., Mendeni, M., Molinari, S., Morotti, A., Luisa Salada, L., Turla, M., Vender, A., Tincani, A., Brucato, A., Franceschini, F., Furloni, R., & Andreoli, L. (2020). Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Annals of the rheumatic diseases, 79(10), 1286–1289.
Schlesinger, N., Firestein, B. L., & Brunetti, L. (2020). Colchicine in COVID-19: an Old Drug, New Use. Current pharmacology reports, 1–9. Advance online publication.
Copyright (c) 2022 Shambo Samrat Samajdar, Shrestha Dutta, Aneek Ghosh, Shatavisa Mukherjee, Jayanta Sharma, Anwesha Behera, Oyendrilla Mitra, Ishanee Das Sharma, Mohojit Chakraborty, Santanu K Tripathi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
